Who Pays for New Drugs? @NewEconomicThinking
Who Pays for New Drugs?  @NewEconomicThinking
Uploaded April 2025 | Updated September 2026, 3 weeks ago
Drug development can better serve public needs—especially in neglected diseases—by reimagining the balance between government, private industry, and nonprofit models.

Fred Ledley, a professor of natural and applied sciences and management at Bentley University, discusses the deep ties between public science funding and private drug development. He traces the origins of this relationship to World War II and highlights how the NIH continues to provide the foundational research behind nearly every new drug. But for diseases of poverty and underserved communities, the for-profit model often fails. Ledley explores the potential of nonprofit biotech organizations—like the TB Alliance—to fill this gap. He challenges assumptions about drug pricing, innovation incentives, and the sustainability of different business models. Ledley argues for policy reforms that recognize the value of nonprofits in global health, while still holding the private sector accountable and leveraging government power to align drug development with public good.

Learn more at https://faculty.bentley.edu/profile/fledley
Who Pays for New Drugs?The Ripple Effect of Automatic EnrollmentCan the Green Transition Work for Workers?Can Universities Survive Politics?Why Does Steve Bannon Fear Joanna Chiu?What Stories Can Teach Us About AgingInvesting In Peace | The Economics of War & Peace Episode 7A Creative Philosophy for Mathematical EconomicsThe Global Role of the DollarThe Big Myth of Market FundamentalismIndia’s Leadership and Global Challenges of Climate and FinanceThe Invisible Economy | TEASER
New Economic Thinking |

Who Pays for New Drugs?

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER